<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://www.med-guidelines.org.uk/index.php?action=history&amp;feed=atom&amp;title=Anti-Phospholipid_Syndrome</id>
	<title>Anti-Phospholipid Syndrome - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://www.med-guidelines.org.uk/index.php?action=history&amp;feed=atom&amp;title=Anti-Phospholipid_Syndrome"/>
	<link rel="alternate" type="text/html" href="https://www.med-guidelines.org.uk/index.php?title=Anti-Phospholipid_Syndrome&amp;action=history"/>
	<updated>2026-11-01T19:13:04Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.39.17</generator>
	<entry>
		<id>https://www.med-guidelines.org.uk/index.php?title=Anti-Phospholipid_Syndrome&amp;diff=2131&amp;oldid=prev</id>
		<title>Frances.Sarkari@anthonynolan.org: /* Acceptability at CT / Work-Up */</title>
		<link rel="alternate" type="text/html" href="https://www.med-guidelines.org.uk/index.php?title=Anti-Phospholipid_Syndrome&amp;diff=2131&amp;oldid=prev"/>
		<updated>2025-03-04T15:25:28Z</updated>

		<summary type="html">&lt;p&gt;&lt;span dir=&quot;auto&quot;&gt;&lt;span class=&quot;autocomment&quot;&gt;Acceptability at CT / Work-Up&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 15:25, 4 March 2025&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l2&quot;&gt;Line 2:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 2:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;QUALIFIED	&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;QUALIFIED	&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br/&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br/&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Acceptability at &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;CT &lt;/del&gt;/ Work-Up==&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Acceptability at &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;VT &lt;/ins&gt;/ Work-Up==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;QUALIFIED&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;QUALIFIED&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br/&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br/&gt;&lt;/td&gt;&lt;/tr&gt;

&lt;!-- diff cache key mg_wiki-mw_:diff::1.12:old-1360:rev-2131 --&gt;
&lt;/table&gt;</summary>
		<author><name>Frances.Sarkari@anthonynolan.org</name></author>
	</entry>
	<entry>
		<id>https://www.med-guidelines.org.uk/index.php?title=Anti-Phospholipid_Syndrome&amp;diff=1360&amp;oldid=prev</id>
		<title>PaulM: /* Explanation of Condition */</title>
		<link rel="alternate" type="text/html" href="https://www.med-guidelines.org.uk/index.php?title=Anti-Phospholipid_Syndrome&amp;diff=1360&amp;oldid=prev"/>
		<updated>2016-06-09T16:29:19Z</updated>

		<summary type="html">&lt;p&gt;&lt;span dir=&quot;auto&quot;&gt;&lt;span class=&quot;autocomment&quot;&gt;Explanation of Condition&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 16:29, 9 June 2016&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l10&quot;&gt;Line 10:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 10:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Explanation of Condition==&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Explanation of Condition==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Autoimmune disorder where antibodies are directed against the cell membrane. May be found in association with SLE (systemic lupus erythematosus) and other autoimmune conditions. Sufferers have episodes of blood clots (thrombosis) or recurrent miscarriage in association with an antiphospholipid antibody or lupus anticoagulant.&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Autoimmune disorder where antibodies are directed against the cell membrane. May be found in association with SLE (systemic lupus erythematosus) and other autoimmune conditions. Sufferers have episodes of blood clots (thrombosis) or recurrent miscarriage in association with an antiphospholipid antibody or lupus anticoagulant.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;See also [[Thrombophilia]]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br/&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br/&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Guidance==&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Guidance==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;

&lt;!-- diff cache key mg_wiki-mw_:diff::1.12:old-604:rev-1360 --&gt;
&lt;/table&gt;</summary>
		<author><name>PaulM</name></author>
	</entry>
	<entry>
		<id>https://www.med-guidelines.org.uk/index.php?title=Anti-Phospholipid_Syndrome&amp;diff=604&amp;oldid=prev</id>
		<title>Dr Robert Lown: Protected &quot;Anti-Phospholipid Syndrome&quot; (‎[edit=sysop] (indefinite) ‎[move=sysop] (indefinite))</title>
		<link rel="alternate" type="text/html" href="https://www.med-guidelines.org.uk/index.php?title=Anti-Phospholipid_Syndrome&amp;diff=604&amp;oldid=prev"/>
		<updated>2012-06-19T11:12:03Z</updated>

		<summary type="html">&lt;p&gt;Protected &amp;quot;&lt;a href=&quot;/Anti-Phospholipid_Syndrome&quot; title=&quot;Anti-Phospholipid Syndrome&quot;&gt;Anti-Phospholipid Syndrome&lt;/a&gt;&amp;quot; (‎[edit=sysop] (indefinite) ‎[move=sysop] (indefinite))&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 11:12, 19 June 2012&lt;/td&gt;
				&lt;/tr&gt;
&lt;!-- diff cache key mg_wiki-mw_:diff::1.12:old-66:rev-604 --&gt;
&lt;/table&gt;</summary>
		<author><name>Dr Robert Lown</name></author>
	</entry>
	<entry>
		<id>https://www.med-guidelines.org.uk/index.php?title=Anti-Phospholipid_Syndrome&amp;diff=66&amp;oldid=prev</id>
		<title>Dr Robert Lown: Page created</title>
		<link rel="alternate" type="text/html" href="https://www.med-guidelines.org.uk/index.php?title=Anti-Phospholipid_Syndrome&amp;diff=66&amp;oldid=prev"/>
		<updated>2012-06-12T11:06:24Z</updated>

		<summary type="html">&lt;p&gt;Page created&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;==Acceptability at Recruitment==&lt;br /&gt;
QUALIFIED	&lt;br /&gt;
&lt;br /&gt;
==Acceptability at CT / Work-Up==&lt;br /&gt;
QUALIFIED&lt;br /&gt;
&lt;br /&gt;
==Individual at Risk==&lt;br /&gt;
Donor / Recipient&lt;br /&gt;
&lt;br /&gt;
==Explanation of Condition==&lt;br /&gt;
Autoimmune disorder where antibodies are directed against the cell membrane. May be found in association with SLE (systemic lupus erythematosus) and other autoimmune conditions. Sufferers have episodes of blood clots (thrombosis) or recurrent miscarriage in association with an antiphospholipid antibody or lupus anticoagulant.&lt;br /&gt;
&lt;br /&gt;
==Guidance==&lt;br /&gt;
Risk of thrombosis, and risk of transmission. Discuss with MO. Not acceptable at any stage if proven antiphospholipid syndrome according to Sydney Criteria. &lt;br /&gt;
&lt;br /&gt;
May donate if has antiphospholipid antibodies/lupus anticoagulant without history of thrombosis or recurrent pregnancy loss.&lt;br /&gt;
&lt;br /&gt;
==Pseudonyms or Related Conditions==&lt;br /&gt;
Hughes Syndrome&lt;br /&gt;
	&lt;br /&gt;
==Version==	&lt;br /&gt;
Version 1, Edition 1&lt;br /&gt;
&lt;br /&gt;
====Date of Last Update====&lt;br /&gt;
15th June 2012&lt;/div&gt;</summary>
		<author><name>Dr Robert Lown</name></author>
	</entry>
</feed>